Ashim Gupta Sells 40,000 Shares of UiPath Inc. (NYSE:PATH) Stock

UiPath Inc. (NYSE:PATH - Get Free Report) CFO Ashim Gupta sold 40,000 shares of the business's stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $21.66, for a total transaction of $866,400.00. Following the transaction, the chief financial officer now directly owns 660,762 shares in the company, valued at approximately $14,312,104.92. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Ashim Gupta also recently made the following trade(s):

• On Friday, March 15th, Ashim Gupta sold 16,000 shares of UiPath stock. The shares were sold at an average price of $22.84, for a total transaction of $365,440.00.
• On Monday, February 5th, Ashim Gupta sold 16,000 shares of UiPath stock. The shares were sold at an average price of $22.47, for a total transaction of $359,520.00.

UiPath Stock Up 0.7 %

PATH traded up $0.15 on Tuesday, reaching $21.80. The company's stock had a trading volume of 5,856,769 shares, compared to its average volume of 9,218,472. The stock has a 50 day moving average of $23.42 and a two-hundred day moving average of $21.33. The company has a market capitalization of $12.40 billion, a price-to-earnings ratio of -128.24 and a beta of 0.96. UiPath Inc. has a fifty-two week low of $12.38 and a fifty-two week high of $27.87.

UiPath (NYSE:PATH - Get Free Report) last announced its quarterly earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.10. The firm had revenue of $405.25 million during the quarter, compared to the consensus estimate of $383.32 million. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. As a group, analysts anticipate that UiPath Inc. will post -0.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on PATH shares. TD Cowen boosted their price target on shares of UiPath from $25.00 to $28.00 and gave the stock an "outperform" rating in a research note on Thursday, March 14th. DA Davidson boosted their price target on shares of UiPath from $20.00 to $24.00 and gave the stock a "neutral" rating in a research note on Thursday, March 14th. Royal Bank of Canada reiterated a "sector perform" rating and set a $29.00 price target on shares of UiPath in a research note on Monday, April 1st. Bank of America boosted their price target on shares of UiPath from $26.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, March 14th. Finally, Mizuho boosted their price target on shares of UiPath from $22.00 to $25.00 and gave the stock a "neutral" rating in a research note on Thursday, March 14th. Nine equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $27.41.

Institutional Investors Weigh In On UiPath

Large investors have recently modified their holdings of the company. Renaissance Capital LLC lifted its holdings in shares of UiPath by 3.0% during the first quarter. Renaissance Capital LLC now owns 250,295 shares of the healthcare company's stock worth $5,674,000 after purchasing an additional 7,269 shares during the period. GAMMA Investing LLC raised its position in UiPath by 40.2% in the first quarter. GAMMA Investing LLC now owns 2,204 shares of the healthcare company's stock worth $50,000 after acquiring an additional 632 shares in the last quarter. Quadrature Capital Ltd raised its position in UiPath by 94.4% in the fourth quarter. Quadrature Capital Ltd now owns 253,112 shares of the healthcare company's stock worth $6,289,000 after acquiring an additional 122,931 shares in the last quarter. PNC Financial Services Group Inc. raised its position in UiPath by 50.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 19,135 shares of the healthcare company's stock worth $475,000 after acquiring an additional 6,385 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in UiPath by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 38,084,858 shares of the healthcare company's stock worth $946,028,000 after acquiring an additional 334,085 shares in the last quarter. 62.50% of the stock is owned by institutional investors and hedge funds.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.